Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Trial details
- Registry ID
- NCT05134441
- Drugs studied
- IMU-838 tablets
TrialRedline tracks 6 clinical trials sponsored by Immunic AG: 2 Phase 3, 1 Phase 2 / 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05134441 | IMU-838 tablets | Active not recruiting | 2026-11Estimated |
| Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05201638 | IMU-838 tablets | Active not recruiting | 2026-11Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)NCT04379271 | IMU-838 | Completed | 2021-01-12Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)NCT03846219 | IMU-838 (10 mg/day), IMU-838 (30 mg/day), IMU-838 (45 mg/day) | Active not recruiting | 2020-04-24Actual |
| Phase 2 Dose-finding IMU-838 for Ulcerative ColitisNCT03341962 | IMU-838 | Terminated | 2022-11-16Actual |
| Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisNCT05054140 | IMU-838 | Unknown | 2025-01-07Estimated |
Names as written in the registry records.
Before: Estimated. After: Actual.
Before: 1050 participants (planned). After: 1100 participants (actual).
Before: Oct 2024. After: Nov 2026.
Before: Recruiting. After: Active not recruiting.
Before: Estimated. After: Actual.
Before: 1050 participants (planned). After: 1121 participants (actual).
Before: Sep 2024. After: Nov 2026.
Before: Recruiting. After: Active not recruiting.